Published in Proc Natl Acad Sci U S A on June 07, 1994
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | NCT05172310
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest (2009) 2.66
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest (2006) 2.64
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc Natl Acad Sci U S A (1996) 1.68
The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A (2003) 1.62
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther (2012) 1.48
Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J (2003) 1.46
The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov (2012) 1.39
Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res (2007) 1.33
Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol (2000) 1.28
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer (2011) 1.24
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst (2012) 1.23
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther (2009) 1.20
Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer (2009) 1.20
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther (2006) 1.17
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry (2007) 1.16
Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc Natl Acad Sci U S A (1998) 1.16
RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci U S A (2009) 1.11
Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol (2012) 1.08
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res (2013) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol (2011) 1.06
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer (2008) 0.98
Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis (2011) 0.97
Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci (2015) 0.97
Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther (2006) 0.97
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol (2012) 0.96
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun (2013) 0.95
Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers. J Exp Clin Cancer Res (2010) 0.95
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer (2009) 0.93
Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. Bioconjug Chem (2012) 0.91
Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV. Bioconjug Chem (2007) 0.90
Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia (2013) 0.90
Peptidomics of the prolyl peptidases. AAPS J (2010) 0.89
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J (2001) 0.89
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med (2013) 0.89
DPP4 in Diabetes. Front Immunol (2015) 0.89
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs (2004) 0.88
Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res (2006) 0.88
Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem (2009) 0.87
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis (2012) 0.86
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology (2009) 0.86
Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol (2013) 0.86
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis (2003) 0.86
Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry (2009) 0.86
Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer (2009) 0.85
Transcriptional regulation of seprase in invasive melanoma cells by transforming growth factor-β signaling. J Biol Chem (2014) 0.84
Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation. PLoS One (2014) 0.84
Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop. Biochem J (2004) 0.84
Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol (2011) 0.82
The role of non-hematopoietic stromal cells in the persistence of inflammation. Front Immunol (2013) 0.82
CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion. BMC Cancer (2013) 0.81
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J (2012) 0.80
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem J (2015) 0.80
Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep (2015) 0.79
Identification and characterization of the promoter of fibroblast activation protein. Front Biosci (Elite Ed) (2010) 0.79
Foramen ovale closure is a process of endothelial-to-mesenchymal transition leading to fibrosis. PLoS One (2014) 0.79
Mouse embryonic fibroblasts exhibit extensive developmental and phenotypic diversity. Proc Natl Acad Sci U S A (2015) 0.78
Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy. Cancer Microenviron (2013) 0.78
Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol (2015) 0.78
Live fibroblast harvest reveals surface marker shift in vitro. Tissue Eng Part C Methods (2014) 0.78
Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells. PLoS One (2015) 0.78
Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. ACS Med Chem Lett (2016) 0.78
Cancer microenvironment and cancer vaccine. Cancer Microenviron (2012) 0.77
Impact of fibroblast activation protein on osteosarcoma cell lines in vitro. Oncol Lett (2014) 0.77
Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin Exp Immunol (2016) 0.76
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget (2016) 0.76
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai) (2015) 0.76
Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. J Biol Chem (2015) 0.76
Scaffold-Free Coculture Spheroids of Human Colonic Adenocarcinoma Cells and Normal Colonic Fibroblasts Promote Tumorigenicity in Nude Mice. Transl Oncol (2016) 0.76
Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. PLoS One (2015) 0.76
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget (2016) 0.75
The application of the fibroblast activation protein α-targeted immunotherapy strategy. Oncotarget (2016) 0.75
Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. Br J Cancer (2000) 0.75
Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer. Cancer Microenviron (2014) 0.75
Cleavage of Type I Collagen by Fibroblast Activation Protein-α Enhances Class A Scavenger Receptor Mediated Macrophage Adhesion. PLoS One (2016) 0.75
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett (2013) 0.75
Fly DPP10 acts as a channel ancillary subunit and possesses peptidase activity. Sci Rep (2016) 0.75
Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity. Cancer Med (2013) 0.75
Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy. Int J Clin Oncol (2015) 0.75
UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-β1-FAP-α. Br J Cancer (2017) 0.75
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Sci Rep (2017) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A (1987) 12.15
Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest (1990) 3.15
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science (1993) 2.40
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci U S A (1981) 2.09
1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol (1989) 2.04
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A (1988) 1.97
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res (1993) 1.50
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A (1991) 1.47
Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci U S A (1992) 1.43
Immunohistochemical analysis of human neuronectin expression in normal, reactive, and neoplastic tissues. J Histochem Cytochem (1989) 1.15
Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. Hum Mol Genet (1993) 1.07
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Tumor necrosis factor (TNF). Science (1985) 8.80
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med (1998) 4.18
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. Proc Natl Acad Sci U S A (1970) 2.77
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet (1977) 2.69
Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med (1968) 2.62
Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol (1996) 2.60
Detection of antibody to autologous human leukemia cells by immune adherence assays. Proc Natl Acad Sci U S A (1977) 2.59
Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer (1989) 2.57
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. Cancer Res (1966) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Thymus cells of radiation-chimeras: TL phenotype, sensitivity to guinea-pig serum, and origin from donor cells. Nature (1965) 2.54
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A (1999) 2.53
Leukemia-associated transplantation antigens related to murine leukemia virus. The X.1 system: immune response controlled by a locus linked to H-2. J Exp Med (1973) 2.52
Serologically demonstrable alloantigens of mouse epidermal cells. J Exp Med (1972) 2.48
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
Horizontal transmission of feline leukaemia virus. Nature (1973) 2.34
Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. Medium to long-term results. J Bone Joint Surg Am (1998) 2.27
Group-specific viral antigens in the milk and tissues of mice naturally infected with mammary tumor virus or Gross leukemia virus. Virology (1968) 2.26
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol (2000) 2.22
Common properties of the oncogenic RNA viruses (oncornaviruses). Virology (1970) 2.20
Wild-type Gross leukemia virus. I. Soluble antigen (GSA) in the plasma and tissues of infected mice. J Natl Cancer Inst (1968) 2.17
The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science (1988) 2.16
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst (1977) 2.15
Age-related changes in cell surface antigens of preleukemic AKR thymocytes. J Exp Med (1976) 2.15
MDM2 gene amplification in metastatic osteosarcoma. Cancer Res (1993) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem (1999) 2.14
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Isoantigens of the H-2 and Tla loci of the mouse: interactions affecting their representation on thymocytes. J Exp Med (1968) 2.11
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci U S A (1981) 2.09
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol (1991) 2.05
Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1987) 2.05
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A (2000) 2.02
Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol (1993) 2.01
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med (1985) 2.00
Osteoid osteoma and osteoblastoma. Current concepts and recent advances. Clin Orthop Relat Res (1986) 1.97
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A (1988) 1.97
Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure. Nature (1970) 1.95
Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. Biochemistry (1967) 1.95
Ly phenotype of cytotoxic T cells for syngeneic tumor. J Exp Med (1976) 1.94
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91